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ABSTRACT 
Objective: The aim of the present study was to prepare a new liquid-solid tablet to enhance the dissolution and bioavailability of a poor water 
soluble calcium channel blocker lacidipine. 
Methods: Firstly, solubility study of lacidipine in different media of water-miscible non-volatile solvents as tween 20, tween 80, propylene glycol, 
liquid paraffin, PEG200, PEG400, and PEG600 was investigated to select the most suitable solvent. A mathematical model was applied to calculate 
the appropriate amount of carrier and coating material. 
Four liquid-solid tablets of 6 mg lacidipine were prepared by dissolving the drug in the previously chosen water miscible non-volatile solvents, then 
a binary mixture of the carrier (Avicel PH 102) and coating material (Aerosil 200) at a ratio of 45:1 was used in all preparation since it gave the 
optimal flow property. Croscarmellose and magnesium stearate were incorporated in all prepared formulas as super disintegrant and lubricant 
respectively. On the other hand, directly compressed lacidipine tablet of the same previous composition without the addition of any non-volatile 
solvent was prepared for comparism study. Both characterizations of powder mixture and post-compression tablet evaluations were done. 
Differential scanning calorimetry (DSC) and fourier transform infrared spectroscopy (FTIR) were investigated for the pure drug, physical mixture, 
and selected liquid-solid tablet to exclude any drug-excipients interaction. 
Results: The obtained results indicated that PEG 200 was the most suitable solvent with lacidipine solubility of 2.81 mg/ml. Flowability of all the 
prepared formulas was found to be within the specification limits. The liquid-solid tablet formula with PEG 200 at 10% w/w lacidipine was the most 
suitable one in the term of disintegration time (21±0.2 second), 100% of drug release within 10 min, and with accepted other tablet properties. 
DSC thermograms for both physical mixture of selected liquisolid system and its tablets illustrated the formation of lacidipine amorphous solid 
solution. The absence of chemical interaction between drug and other formula components was confirmed by remaining all characteristic peaks of 
lacidipine in all investigated FTIR spectra. 
Conclusion: Liquid-solid tablet was considered as a promising system to enhance solubility and dissolution rate of poor-water soluble lacidipine.  
Keywords: Lacidipine, Solubility, Liquid-solid system, Dissolution rate  
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijap.2018v10i1.22313 
 
INTRODUCTION  
The poor dissolution rate of water-insoluble drugs is still a 
substantial problem confronting the pharmaceutical industry. A 
great number of new and possibly, beneficial chemical entities do 
not reach the public merely because of their poor oral bioavailability 
due to inadequate dissolution [1]. 
Due to their low bioavailability, poorly water-soluble drugs cause 
many difficulties in the development of pharmaceutical dosage 
forms for oral delivery [2]. Different techniques have been published 
in the scientific literature to enhance the dissolution profile and also 
the absorption efficiency and bioavailability of water-insoluble 
and/or liquid lipophilic drugs.  
Reduction of the particle size via micronisation or nanonisation leading 
to the increased surface area, use of surfactants, lyophilisation, use of co-
solvents, self-emulsification and self-microemulsification [2-3].  
The most promising and innovative technique for promoting 
dissolution and in vivo bioavailability of poorly soluble drugs is the 
formulation of liquisolid systems [4]. Its main advantages include 
simplicity of manufacturing, use of commercially available 
excipients, and application of well-known methods and equipment 
utilized for the manufacturing of conventional tablets [5]. 
The liquisolid systems are generally considered as acceptably flowing 
and compressible powdered forms of liquid medications (that implies 
liquid lipophilic (oily) drugs, or water-insoluble solid drugs dissolved in 
suitable water-miscible nonvolatile solvent systems [6].  
Such liquid medicament may be converted into a dry looking, non-
sticky, acceptably flowing, and easily compressible powders by a 
simple admixture with selected powder excipients referred to as the 
carrier and coating materials [7]. The technique of liquisolid 
compacts has been successfully employed to improve the in vitro 
release of poorly water-soluble drugs such as carbamazepine, 
famotidine, piroxicam, indomethacin, hydrocortisone, naproxen, 
furosemide, and prednisolone [8]. 
Lacidipine (LCDP) is chemically a 1, 4-dihydropyridine derivative, 
which is pharmacologically a calcium channel blocker used as an 
anti-hypertensive drug. LCDP works by blocking calcium channels in 
the arterial wall those are present in the muscle cell [9]. The 
chemical structure of lacidipine was shown in fig. (1) 
 
 
Fig. 1: Chemical structure of lacidipine [10] 
 
In the present study, a poorly soluble calcium channel blocker 
lacidipine were prepared as liquisolid compacts using water-miscible 
non-volatile solvents to enhance solubility and the dissolution rate 
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with compare the in vitro drug release profile of formulated liquisolid 
tablets with the prepared direct compressed tablet. 
MATERIALS AND METHODS 
Materials  
The following materials were used: Lacidipine was purchased from 
Hangzhou Hyper Chemical Limited, China., Avicel PH 102 and Aerosil 
200 (Wuhan Senwayer Century chemical Co., Ltd), croscarmellose 
sodium (Rajesh Chemicals, Mumbai; India), Propylene glycols, 
polyethylene glycol (PEG 200), polyethylene glycol (PEG 400), 
polyethylene glycol (PEG 600), tween 80, tween 20 and liquid 
paraffin were obtained from SD Fine Chem Ltd., Mumbai, India. All 
reagents used were of analytical grade.  
Methods 
Solubility studies  
Solubility studies of lacidipine were carried out in water, tween solution, 
propylene glycol, PEG 200, PEG 400, PEG 600, tween 80, tween 20 and 
liquid paraffin. Saturated solutions were prepared by adding an excess 
drug to the vehicles and shaking in a water bath with a shaker for 48h at 
25±0.5 °C under constant vibration. After this period the solutions were 
filtered, diluted and analyzed by spectrophotometer at λmax
In this study, PEG 200, Microcrystalline Cellulose (Avicel PH 102-
MCC), and Aerosil 200 were used as a liquid vehicle, carrier, coating 
respectively. The concentration of the drug in the liquid vehicle was 
varied and the carrier: coating ratio was kept constant in all 
formulations (R=45:1). 
 282 nm 
(cary, Australia). Three determinations were carried out for each sample 
to calculate the solubility of lacidipine. 
Application of the mathematical model for designing the 
liquisolid systems 
A powder can only retain a limited amount of liquid medication 
while maintaining acceptable flowability and compressibility. 
Therefore, in order to attain a liquisolid system with acceptable 
flowable and compressible properties,a mathematical model 
introduced and validated by Spireas is recommended to calculate the 
appropriate quantities of carrier and coating material [11].  
The model is based on two fundamental properties of a powder, i.e., 
flowable liquid retention potential (Φ value) and compressible 
liquid retention potential (Ψ value). The Φ and Ψ values of a powder 
excipient represent the maximum quantity of liquid vehicle that can 
be retained in the powder bulk without compromising flowability 
and compressibility [12]. 
Depending on the excipient ratio (R) of the powder substrate an 
acceptably flowing and compressible liquisolid system can be 
obtained only if a maximum liquid load on the carrier material is not 
exceeded. This liquid/carrier ratio is termed “liquid load factor Lf
L
 
[w/w] and is defined as the weight ratio of the liquid formulation 
(W) and the carrier material (Q) in the system:  
f 
R represents the ratio between the weights of the carrier (Q) and the 
coating (q) material present in the formulation:  
= W ÷ Q------ (1) 
R = Q ÷ q------ (2) 
The liquid load factor that ensures acceptable flowability (Lf
Lf = Φ+φ. (1/R) ----- (3) 
) can be 
determined by:  
Where Φ and φ are the Ф -values of the carrier and coating material, 
respectively [13].  
In order to calculate the required ingredient quantities, the flowable 
liquid retention potentials (Φ-values) of powder excipients were 
utilized. In polyethene glycol 200, the Φ-value of Avicel PH 102 was 
found to be 0.007 and the φ-value for Aerosil 200 was 3.26.  
So, by knowing both Lf
Preparation of lacidipine liquisolid compact 
Four liquisolid tablets denoted (F1 to F4) containing 6 mg of lacidipine 
were prepared by dispersing in the non-volatile vehicle, by choosing a 
non-volatile solvent for dissolving the drug. From the results of 
solubility studies, PEG 200 is chosen as the liquid vehicle due to higher 
solubility profile of lacidipine in it. Then a bindery mixture of the 
carrier (Avicel PH 102) and coating material (Aerosil 200) was 
prepared at a ratio of 45: 1, by continuous mixing for a period of 10 
min in a mortar. The amount of carrier and coating materials are 
enough to maintain acceptable flow and compression properties. R 45 
was used in all formulations since it gave the optimal flow property. 
 and W, the appropriate quantities of carrier (Q) 
and coating (q) powder materials required to convert a given amount 
of liquid medication (W) into an acceptably flowing and compressible 
liquisolid system could be calculated from equation (1) and (2). 
Finally, a 5 %w/w of croscarmellose as a super disintegrant was 
added and mixed for 10 min then 1 % w/w of magnesium stearate as 
a lubricant was added into the mixture and mixed for 2 min. The 
final mixture was compacted using a single punch-tablet machine 
(Korsch EKO, Germany). The composition of liquisolid tablets was 
shown in the table (1). 
 
Table 1: Formulation of lacidipine liquisolid tablets prepared using PEG-200 
Formula Lacidipine 
concentration In 
liquid medication 
(%w/w) 
(R) 
Q: 
q 
 
Loading 
factor 
(Lf) 
W/Q 
PEG 
200 
(mg) 
Lacidipine 
(mg) 
Avicel 
PH 102 
Q (mg) 
 
Aerosil 
200 
q (mg) 
 
Crosscarmelose 
5% (mg) 
Magnesium 
stearate 1% 
(mg) 
 
Unit 
dose 
(mg) 
F1 10 45 0.079 54 6 759.5 17 42 8.78 887 
F2 15 45 0.079 34 6 506 11.2 28 5.8 591 
F3 20 45 0.079 24 6 380 8.4 21 4.4 443.8 
F4 25 45 0.079 18 6 304 6.8 16.7 3.5 355 
 
Preparation of directly compressed tablets (DCT) 
Compressed tablet containing 6 mg of lacidipine was prepared with 
direct compression method without addition of any non-volatile 
liquid vehicle. The lacidipine powder was mixed with suitable 
amounts of considered carrier and coating material. Afterwards, 5% 
of crosscarmelose was added as a disintegrant and mixed, and then 
1% of lubricant was added to the mixture. The final blend was 
compressed using Korsch (Germany) tablet machine [14]. 
Pre-compression studies 
Characterization of powder mixture 
Angle of repose 
The frictional force in a loose powder can be measured by the 
angle of repose. The angle of Repose is the maximum angle 
between the surface of a pile of powder and horizontal plane. It 
is usually determined by Fixed funnel Method.  
A funnel was secured with its tip at a given height (h), above a 
Petri dish is placed on a flat horizontal surface. The blend 
carefully pored through the funnel until the apex of the conical 
pile just touches the tip of the funnel. The radius (r) of the base 
of the conical pile was measured. 
The angle of repose (θ) was calculated using the following formula:  
Tan θ = h ÷ r 
Where; θ = Angle of repose  
h = Height of the cone in cm  
r = Radius of the cone base in cm 
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The compressibility index (Carr’s Index)  
Carr’s Index is a measure of the propensity of a powder to be 
compressed. It is determined from the bulk and tapped densities and 
is calculated using the following formula [15].  
Carr’s index = Tapped density−Bulk density
Tapped density
 x100 
Bulk density = w
vo
  
Taped density= w
vf
  
Where w is weight of powder 
V o is volume of powder 
V f  
Sink conditions were maintained throughout the study. The samples 
were then analyzed at 284 nm by UV/visible spectrophotometer. 
The study was carried out in triplicate [23]. 
is taped volume of powder  
Post-compression studies 
Hardness  
The hardness of the tablet was determined using Monsanto hardness 
tester. Three tablets were randomly selected from each formulation 
and hardness of the same was determined [16]. The average value 
was calculated. 
Friability testing  
Friability of the tablets was determined by using Roche friabilator. 
Ten tablets from each batch were placed in the friabilator and 
rotated at 25rpm for a period of 4 min. The friability was determined 
using the following formula. 
Percentage friability= W1−W2
W1
x100 
Where the W1=Initial weight of 20 tablets, W2=Weight of the 20 
tablets after testing [17]. 
Weight variation 
Twenty tablets were taken and their weight was determined 
individually and collectively on a digital weighting balance. The 
average weight of one tablet was determined from the collective 
weight and comparing the individual tablet weight to average weight 
variation tolerance [18]. 
Drug content 
Ten tablets were crushed in a mortar and the powder equivalent 
to 6 mg of lacidipine was weighed and dissolved in 10 ml of 
methanol in a 100 ml volumetric flask and the volume was made 
with 1% tween 20 solutions. This solution was further diluted with 
1% tween 20 if necessary and the absorbance was measured at 
282 nm [19]. 
Disintegration test 
The disintegration time was determined in water maintained at 
37±2 C̊.  The disintegration apparatus with a basket rack 
assembly containing six open-ended tubes and 10-mesh screen 
on the bottom was used. A tablet was placed in each tube of the 
basket and the time for complete disintegration of the six tablets 
was recorded [20-22]. 
In vitro drug dissolution test 
The dissolution rates of all formulations were measured by using 
tablet dissolution apparatus USP Type II. Dissolution studies were 
carried out using 500 ml of purified water with 1% w/v polysorbate 
20, at 50 rpm and at temperature of 37±0.5 C˚. 10 ml aliquots were 
withdrawn at suitable time interval (5, 10, 15, 20, 25, 30, 35, 40 and 
45 min), filtered through syringe filter 0.45µm and diluted as per 
need and replaced with fresh medium.  
Comparison of dissolution rate 
The model-independent approach was applied for comparison of 
dissolution profiles. For the comparison of dissolution data for 
each formulation, percentages of drug dissolved at 10 min (Q10 
min), 45 min (Q45 min), mean dissolution time (MDT) and 
percentage of dissolution efficiency (DE) at the end of 45 min 
were calculated using DD solver software in order to select the 
optimized formula. 
The dissolution profile of the optimized formula and the DCT was 
compared on the basis of their similarity factor (f2) and dissimilarity 
factor (f1). These parameters were determined for tablets from the 
optimal formulation of liquisolid compact and direct conventional 
tablet of lacidipine. 
Dissimilarity factor was calculated using Equation (1) and similarity 
factor was calculated using Equation (2). 
f1 = ∑ =1|Rt−Tt|
n
t
∑ =1Rtnt
× 1004T--------------Equation 1 
Where n is the sampling number, Rj and Tj are the percents 
dissolved of the reference and test products at each time point j. The 
f1 value between 0 and 15 [24]. 
f2 ∑
=
−
n
t
tt TR
1
)(= 50 log {[1 + 1
n
)] − 0.5 × 100} 4T------------Equation 
2 
Where n is the number of time points at which % dissolved was 
determined, Rt is the % dissolved of one formulation at a given 
time point, and Tt is the % dissolved of the formulation to be 
compared at the same time point. The similarity factor fits the 
result between 0 and 100. It is 100 when the two dissolution 
profiles are identical and approaches 0 as the dissimilarity 
increases. An f2 above 50 indicates that the two profiles are 
similar [25]. 
Drug-polymer interaction studies 
Differential scanning calorimetry (DSC) 
Samples (3-5 mg) were placed in an aluminum pan and heated in 
the DSC-60 (Shimadzu, Japan) at a constant rate of 10 °C/min, in 
an atmosphere of nitrogen over a temperature range of 25-300 
°C. The DSC studies were performed on the pure drug, a physical 
mixture of liquisolid system and on the selected liquisolid tablet 
[26]. 
Fourier-transform infrared spectroscopy (FTIR) 
It was performed using the Infrared spectrophotometer (Lambda 
7600, Australia). Samples of 2-3 mg were mixed with about 100 mg 
of dry potassium bromide powder and compressed into transparent 
discs then scanned over a wave range of 4000-400 cm-1
RESULTS AND DISCUSSION 
in FTIR 
instrument. The IR spectra were performed on the pure drug, a 
physical mixture of liquisolid system and on a selected liquisolid 
tablet [27]. 
Statistical analysis  
All the results were expressed as the mean value±standard deviation 
(SD). One way analysis of variance (ANOVA) was used to test for 
significance, at a 5% significance level. Statistical difference dealing 
(P<0.05) was considered significant [28]. 
Saturation solubility studies 
The solubility of lacidipine in different media is presented in table 2 
and fig. 2. Drug solubility in a non-volatile vehicle is the most 
important aspect in liquisolid systems. The solubility of the drug 
contributes to molecular dispersion in a non-volatile solvent which 
will improve the dissolution rate. 
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Table 2: Solubility of lacidipine in different media 
Medium Solubility (mg/ml)  
Water 0.044±0.0035 
Tween solution  0.09±0.006  
Tween 20 1.413±0.0635 
Tween 80 5.486±0.0104 
Propylene glycole 1.4883±0.01 
Liquid paraffin 0.823±0.123 
PEG 200 2.81±0.2 
PEG 400 2.523±0.05 
PEG 600 2.654±0.0582 
(Reading Represent the mean±SD, n =3) 
 
From the solubility profile, it can be judged that the drug was soluble 
in most the non-polar liquid vehicles and very slightly soluble in water. 
And amongst the non-polar liquid vehicles the drug has the highest 
solubility in PEG 200 and tween 80, but due to its viscosity, tween 80 
was not chosen to prepare the liqisolid. Increasing the moisture 
content of carrier materials may result in decreased powder 
flowability [29]. So, PEG 200 was the appropriate solvent in the 
preparation of lacidipine liquisolid tablets. 
 
 
Fig. 2: Drug solubility profile of lacidipine, (reading represent the mean±SD, n =3) 
 
Flowable liquid retention potential (Ф value) and liquid load 
factor (Lf)  
Ф value of Carrier and Coat materials in polyethene glycol 200 were 
cited in the literature and found to be 0.007 and 3.26 respectively. 
According to mathematical model proposed by Spireas et al. 
equation for Avicel PH-102 and Aerosil 200 in polyethene glycol 200 
was calculated by using R value = 45 as  
𝐋𝐋𝐟𝐟 = 𝟎𝟎.𝟎𝟎𝟎𝟎7+𝟑𝟑.𝟐𝟐𝟔𝟔 (𝟏𝟏/𝐑𝐑) 
So, f = 0.079 
Precompression evaluation 
Angle of repose  
Flowability of a powder is of critical importance in the formulation 
and industrial production of tablet dosage form. As a general guide, 
powders with angles of repose greater than 50 have poor flow 
properties, whereas minimum angles close to 25 correspond to very 
good flow properties [30]. 
The results of the angle of repose and carr’s index were given in the 
table 3. The results showed that angle of repose was ranged from 
33.5˚ to 36.3˚for the formulated liquisolid powder, while the angle of 
repose for DCT was 25˚ meaning excellent flowability due to the 
absence of the liquid vehicle. It was found that formula of highest 
drug concentration in PEG 200 has better flowability than another 
formula due to fewer amounts of vehicle presents. And the results of 
carr’s index were proved all formulations shown flow property 
ranged from fair to poor. 
From table 3, it can be concluded that all the formulas were found to 
be within the specification limits. 
Hardness test 
The hardness of the prepared tablets of all formulations is within the 
acceptable limit. The hardness of tablets prepared by direct compression 
was found to be from 6 to 10 kg/cm2
 
 as shown in table 4. Generally, the 
ideal tablet hardness should be produced without applying excessive 
compression force where rapid tablet disintegration and drug 
dissolution are maintained at the same time [31]. 
Table 3: Flow properties of lacidipine liquisolid powder 
Formula Angle of repose Type of flow Carr’s index Type of flow 
F1 36±1.1 Fair 21.8±2.4 Fair 
F2 36±1.6 Fair 23±2.8 Poor 
F3 34±2.5 Good 21.3±1.5 Fair 
F4 33.5±3.1 Good 20±2.5 Fair 
DCT 25±2.1 Excellent 15±1 Good 
(Reading Represent the mean±SD, n =3) 
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Friability test 
All lacidipine tablets had acceptable friability as none of the tested 
formulas exceeded 1% loss in tablet weight as shown in table 4; also, 
no tablet was cracked, split or broken in either formulation. Since all 
the prepared formulas met the standard friability criteria, they are 
expected to show acceptable durability and withstand abrasion. 
Disintegration time 
The disintegration time for the prepared lacidipine liquisolid tablets 
was shown in table 4. It was found that, the mean of the 
disintegration times for all investigated tablets was less than 1 min, 
due to the effect of superdisintegrants, microcrystalline cellulose 
and croscarmellose accelerate the disintegration of the liquisolid 
compact and as the drug concentration in liquid medication 
increases, and the disintegration time is increased [32].  
Weight variation 
Tablets of each formula were subjected to weight variation test, the 
difference in weight and percent deviation was calculated for each 
tablet. The results of the test as demonstrated in table 4 showed 
that, the tablet weights were within the pharmacoepial limit. 
Drug content  
The results indicate that the contents for tablets of all the 
formulations were uniform and contains a therapeutic dose of the 
active ingredients as shown in table 4. 
 
Table 4: Evaluation of different parameters of liquisolid tablet and DCT 
Formula Hardness 
(Kg/cm2
Friability 
) (%) 
Disintegration time (s) 
 
Content uniformity 
(%) 
Weight variation 
(mg) 
F1 10±0.6 0.18 21±0.2 100±0.4 883.75±2.4 
F2 9±0.3 0.4 13±0.6 85±0.3 589.8±2.7 
F3 6±0.3 0.77 25±0.7 100±0.2 442.7±2 
F4 6±0.3 0.14 39±0.2 85±0.2 352.7±1.6 
DCT 10±1.6 0.4 23±0.2 100±0.1 829.3±4.8 
(Values represent the mean±SD, n =3) 
 
In vitro drug dissolution studies 
The results of in vitro drug released at different time intervals is plotted 
against time to obtain the dissolution profiles as shown in fig. 3 and 4. 
Liquisolid formulations initially show greater release than DCT. 
MDT, Q10 min, Q45 min and DE of each liquisolid formula and 
DCT were calculated in tween 20 solutions and reported in table 
5. 
 
Table 5: Dissolution parameters of liquisolid compacts and DCT 
Formula Q10 min Q45 min MDT (min) %DE 
F1 100±0.9 98±0.3 3.83 90 
F2 55±1.2 100±0.6 11.6 74 
F3 83±2 100±1 6.95 85 
F4 58±0.5 100±1 10.35 77 
DCT 48±0.7 90±0.4 12.72 65 
(Reading represent the mean±SD, n =3) 
 
The results in the table clearly affirm that the liquisolid tablet F1 had 
the highest percentage 100 % of lacidipine dissolved in 10 min, 
while 48% of the drug was released from DCT. All liquisolid tablets 
show completely 100% of drug release at 45 min. However, DCT 
show less drug release at this time. 
DE is commonly applied for comparison of dissolution profiles to 
decide better formulation. DE of F1 was found to be 90%. Higher DE 
indicated that liquisolid compact has significantly enhanced 
dissolution rate (p<0.05). From the result, it is concluded that 
concentration of drug in liquid medication is an important factor in 
drug release [33]. A decrease in concentration of drug in PEG 200 
increases the dispersion of drug at molecular level which may 
further enhance the dissolution rate of the drug [34]. 
Lower MDT values indicated faster release of drug from liquisolid 
formulation, MDT of DCT was found to be 12.72 min while that of 
formulation FA3 was 3.83 minute. Hence the formula (F1) was 
considered as the optimized tablet.  
Pairwise procedure such as dissimilarity (f1) and similarity (f2) 
factors provides a simple way to compare dissolution data. FDA 
guidance proposes that f1 value between 0 and 15
In comparison between optimized tablet F1 and DCT, f1 value was 
36.74>15 and f2 values were 26.43<50 indicate nonequivalence in 
dissolution profile between F1 and DCT. 
 and f2 value 
between50-100 indicate equivalence in dissolution profiles.  
Such enhanced drug 
dissolution rate may be mainly attributed to the fact that this poorly-
water-soluble drug is already in solution in PEG 200, while at the 
same time, it is carried by the powder particles (microcrystalline 
cellulose-silica) of the liquisolid vehicle. Thus, its release is 
accelerated due to its markedly increased wetability and surface 
availability to the dissolution medium [35]
Differential scanning calorimetry (DSC) 
. 
The DSC thermogram of the drug in fig. 5 depicts a sharp 
endothermic peak at 186 °C corresponding to the melting 
temperature of lacidipine. Such sharp endothermic peak signifies 
that drug used was in the pure crystalline state [36]. A complete 
disappearance of the drug melting peak was observed in the physical 
mixture of optimized liquisolid system F1 and its tablet as shown in 
fig. 6 and 7 respectively, a fact that agrees with the formation of drug 
solution in the liquisolid powdered system, i.e., the drug was 
molecularly dispersed within the liquisolid matrix and also indicate 
the formation of an amorphous solid solution [37]. 
Fourier-transform infrared spectroscopy (FTIR) 
The FTIR spectrum of lacidipine, physical mixture and liquisolid tablet 
of F1 was illustrated in fig. 8, 9 and 10 respectively. The characteristic 
absorption peaks of lacidipine appeared at 3348.78, 2978.52 to 2808, 
1702 to 1653.66, 1629.55 and 1292 cm-1, respectively, denoting 
stretching vibration of-NH of dihydropyridine ring,-CH-,-C=O,-C=C 
functional groups and ester group([38]). The optimized liquisolid 
system showed characteristic peaks of lacidipine and carriers. These 
results indicated that there is no chemical interaction between drug 
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and carrier when formed as a liquisolid system. As shown in fig. 9 and 
10, there is a reduction in intensity of the characteristic absorption 
bands of drug in liquisolid formulations which might be attributed to 
the hydrogen bonding interaction of the amin group of lacidipine with 
the hydroxyl group of the PEG 200. This resulted in drug dissolution 
enhancement as shown by dissolution data [34]. 
 
 
Fig. 3: Dissolution profile of lacidipine from liquisolid compact (Data expressed as a mean±SD, n =3) 
 
 
Fig. 4: Dissolution profile of lacidipine from F1 and direct conventional tablet, (data expressed as a mean±SD, n =3) 
 
 
Fig. 5: DSC thermogram of lacidipine 
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Fig. 6: DSC thermogram of a physical mixture of F1 liquisolid system 
 
 
Fig. 7: DSC thermogram of F1 liquisolid tablet 
 
 
Fig. 8: FTIR spectrum of lacidipine 
 
 
Fig. 9: FTIR spectrum of a physical mixture of F1 liquisolid system 
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Fig. 10: FTIR spectrum of F1 liquisolid tablet 
 
CONCLUSION 
The overall objective of present study was to enhance dissolution of 
poorly water-soluble lacidipine by liquisolid compact technique. The 
liquisolid tablets formulated with the PEG 200 at a drug 
concentration of 10% w/w is the best formulation among all the 
batches of liquisolid tablets prepared, in terms of faster 
disintegration time, superior dissolution profile, and acceptable 
tablet properties. PEG 200 was found to be a promising liquid 
vehicle in formulating liquisolid formulations of lacidipine. The 
liquid vehicle plays a contributing role in improving the dissolution 
profiles of a poorly water-soluble drug in the liquisolid formulations. 
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